ethyl 6-sulfamoylhexanoate | 848432-25-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl 6-sulfamoylhexanoate
• CAS: 848432-25-7
• 化学式: C₈H₁₇NO₄S
• 分子量: 223.293
• InChiKey: IDJZOWZPEUZHNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  14
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  94.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  酮基布洛芬 、 N-羟基-7-氮杂苯并三氮唑 、 1,2-二氯乙烷 、 ethyl 6-sulfamoylhexanoate 在 盐酸 、 magnesium sulfate 作用下， 以 二氯甲烷 为溶剂， 反应 72.0h， 以yielded 2.0 g (44%) of the title compound的产率得到6-[2-(3-Benzoylphenyl)propionylsulfamoyl]hexanoic acid
  参考文献：
  名称：

  Plasma protein affinity tags

  摘要：

  增加治疗剂在血浆中半衰期的方法和新型多肽衍生物。

  公开号：

  US07897560B2
• 作为产物：
  描述：

  在 sodium hydride 作用下， 以 四氢呋喃 、 二氯甲烷 、 mineral oil 为溶剂， 以26 mg的产率得到ethyl 6-sulfamoylhexanoate
  参考文献：
  名称：

  光催化羧酸盐到亚磺酰胺的转换实现了磺酰胺和磺酰亚胺的不同合成

  摘要：

  亚磺酰胺、磺酰胺和磺酰亚胺是药物化学中的热门基序，但从简单易得的原料开始合成烷基变体的方法却很少。此外，通常需要对每一类分子进行定制合成。在本报告中，我们详细介绍了这三种不同的硫官能团的合成，使用易于获得且结构多样的烷基羧酸作为起始材料。该方法利用吖啶光催化剂和 400 nm 光从羧酸产生烷基自由基，随后将自由基加成到亚磺胺试剂上，从而产生亚磺酰胺产品。使用N-烷氧基亚磺胺试剂t -BuO-NSO 作为自由基捕获剂，提供常见的N-烷氧基亚磺酰胺中间体，通过分别用氢氧化钠或胺处理，可以以不同的方式将其转化为磺酰胺或磺酰亚胺。该反应具有可扩展性，可耐受多种官能团，可用于复杂生物活性化合物的多样化。

  DOI：

  10.1021/jacs.3c07974

文献信息

• Novel plasma protein affinity tags
  申请人：Dorwald Zaragoza Florencio

  公开号：US20070105750A1

  公开（公告）日：2007-05-10

  Method for increasing half-life of therapeutic agents in plasma and novel polypeptide derivatives.

  增加治疗药物在血浆中半衰期的方法和新型多肽衍生物。
• Novel Plasma Protein Affinity Tags
  申请人：Dorwald Florencio Zaragoza

  公开号：US20100184641A1

  公开（公告）日：2010-07-22

  Method for increasing half-life of therapeutic agents in plasma and novel polypeptide derivatives.

  增加治疗药物在血浆中半衰期的方法和新的多肽衍生物。
• ALBUMIN-BINDING DERIVATIVES OF THERAPEUTIC PEPTIDES
  申请人：NOVO NORDISK A/S

  公开号：EP1667724A2

  公开（公告）日：2006-06-14
• US7897560B2
  申请人：——

  公开号：US7897560B2

  公开（公告）日：2011-03-01
• [EN] NOVEL PLASMA PROTEIN AFFINITY TAGS<br/>[FR] NOUVELLES ETIQUETTES D'AFFINITE POUR LES PROTEINES PLASMIQUES
  申请人：NOVO NORDISK AS

  公开号：WO2005028516A2

  公开（公告）日：2005-03-31

  The present invention relates to a new drug delivery system, based on novel compounds with high affinity to plasma proteins (= affinity tags). These affinity tags can be linked to therapeutically active compounds and thereby enhance their half-life in plasma by reversible binding to plasma proteins.The present invention intends to provide a versatile delivery system for therapeutic agents, such as proteins, peptides, or small molecule drugs, by covalently binding these therapeutic agents to a plasma-protein ligand, capable of reversible binding to one or several plasma proteins. We have designed a novel linking strategy which enables the covalent binding of known, plasma-protein binding carboxylic acids to a broad variety of therapeutic peptides or proteins, or to any other type of compound, of which a prolonged periferal exposure at well-defined concentrations is required. This strategy consists in converting said plasma-protein binding carboxylic acid into a carboxylic acid mimetic, having a pKa between -5 and +7, in order to be ionized to a significant extent in plasma. Such a carboxylic acid mimetic could be, for instance, an N-acylsulfbnamide, which contains an additional functional group which enables covalent binding of the acid mimetic to a therapeutic agent. This linking strategy should not significantly disturb the structure of the plasma-protein binding acid, if a suitable acid mimetic has been chosen. The present invention álso relates to a compound of the general formula (II), wherein R1, G, Z, X, and Y are defined as described. The present invention also relates to pharmaceutical compositions comprising a compound according to the present invention and the use of compounds according to the present invention for preparing medicaments for treating disease.